Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by James Picern..
Europe’s Natural Gas Prices Soar to 4-Year High as Winter Looms
Europe’s benchmark price jumped by 2% at opening in Amsterdam on Monday, extending the 7% weekly gain from last week, as concerns mount that the gas withdrawal season has started amid no signs that Qatar’s LNG flows would return anytime soon. The front-month price at the Dutch Title Transfer Facility (), the benchmark for Europe’s gas trading, rose by 2.1% to as much as $107.40 (95.73 euros) per megawatt-hour (MWh) early on Monday, reaching its highest level since 2022.
Earnings call transcript: Ather Energy posts first positive PAT in Q2 2026
Ather Energy said quarterly revenue and demand continued to rise sharply in Q2 FY27, while adjusted gross margin improved and the company posted its first positive EBITDA and positive profit after tax. The electric scooter maker also said its shares were up 13.96% to $1,572.6, near the top of their 52-week range, as investors reacted to the profitability milestone, strong volume growth and early demand for its new KONARC model.
Earnings call transcript: JK Tyre Q2 2026 revenue miss weighs on shares
JK Tyre & Industries reported a 20% rise in quarterly revenue and stronger operating profit in Q2 FY 2027, but the stock fell 2.93% to $300.10 after the company’s revenue came in below Wall Street expectations. Revenue reached INR 4,850 crores, or about $46.05 billion, compared with a forecast of INR 4,710 crores, a miss of 2.23%.
H.C. Wainwright initiates Electra stock coverage with buy rating
Investing.com - H.C. Wainwright initiated coverage on Electra Therapeutics () with a buy rating and a price target of $30.00, the firm said Monday. The target represents substantial upside from the current stock price of $8.71, which is trading near its 52-week low of $8.50. According to InvestingPro data, the stock appears overvalued relative to its Fair Value, though analysts maintain a strong buy consensus.
Cemex stock rises 3% on third quarter earnings and revenue beat
Investing.com -- On Monday, Cemex, S.A.B. de C.V. () reported third quarter that exceeded analyst expectations, with adjusted earnings per ADS of $0.28 compared to the consensus estimate of $0.24. Shares of the company rose 2.84% in pre-market trading following the results. Revenue reached $4.59 billion, surpassing the $4.45 billion consensus and representing an 8% increase from $4.25 billion in the third quarter of 2025.
MakeMyTrip stock rises 4% on profit view despite revenue miss
Investing.com -- On Monday, MakeMyTrip Limited () reported second quarter fiscal 2027 that met earnings expectations but fell short on revenue. Shares of the company rose 4.78% as strong domestic travel demand and improved profitability offset concerns about the top-line miss. The stock’s positive movement reflected investor focus on profitability improvements, with adjusted operating profit rising to $46.2 million from $44.2 million YoY.
Northland upgrades Sono-Tek stock rating citing order backlog
Investing.com - Northland upgraded Sono-Tek () to Outperform from Market Perform on Monday and set a price target of $7.00. The firm said the company is positioned for a record fiscal year 2028 and the current valuation is attractive. Sono-Tek has announced $10.8 million in orders to be delivered next fiscal year. The company typically generates more than $4.0 million in recurring parts and service revenue each year.
Guggenheim reiterates Climb Bio stock rating on kidney drug data
Investing.com - Guggenheim reiterated a Buy rating and $35.00 price target on Climb Bio () following updates on the company’s drug candidates presented at ASN Kidney Week 2026. The stock currently trades at $10.19, representing significant upside potential to the analyst target. Shares have surged over 400% in the past year, though InvestingPro analysis suggests the stock is trading near its Fair Value.
Susquehanna maintains Caesars stock rating at neutral, $31 target
Susquehanna maintains Caesars stock rating at neutral, $31 target Susquehanna maintains Caesars stock rating at neutral, $31 target In this article: Investing.com - Susquehanna reiterated a neutral rating on Caesars Entertainment Inc. () shares with a $31 price target. The firm lowered its third-quarter 2026 estimates for the casino operator while keeping the price target unchanged. The target aligns with Fertitta’s acquisition price.
Vodafone Qatar Q3 FY26 slides: profit surges 24%, outlook upgraded
Introduction & Market Context presented its financial performance for the nine months ended September 30, 2026, on October 26, 2026, revealing robust profitability growth that prompted the company to upgrade its full-year guidance. Despite quarterly revenue coming in slightly below analyst expectations, the stock rose 3.2% to $2.42, as investors focused on the company’s improved margins, accelerating profit growth, and raised outlook for the remainder of fiscal 2026.
Ather Energy Q2 FY27 slides: first profit amid product expansion
Introduction & Market Context unveiled its Q2 FY27 earnings presentation on October 26, 2026, highlighting a historic profitability milestone alongside the launch of KONARC, its new mainstream electric scooter. The company reported its first positive EBITDA and profit after tax while navigating significant commodity inflation, marking a turning point for the Indian electric two-wheeler manufacturer.
Guggenheim cuts Legence stock price target to $90 on valuation
Investing.com - Guggenheim lowered its price target on Legence Corp () to $90 from $115 while maintaining a Buy rating on the stock. The firm updated its financial estimates for Legence following recent conversations with management, with projections for 2027 and 2028 moving higher. The price target reduction reflects a more conservative assessment of the valuation environment, according to the firm. The new $90 target implies EBITDA multiples of 18.7x and 15.5x for 2026 and 2027, respectively.
Chardan reiterates Gossamer Bio stock rating on PAH drug outlook
Investing.com - Chardan reiterated a Buy rating and $160.00 price target on Gossamer Bio Inc. () following the firm’s 10th Annual Healthcare Conference. The stock currently trades at $9.61 with a market cap of $58.75 million, and InvestingPro analysis suggests the shares are undervalued relative to its Fair Value estimate.
Why is Pics stock plummeting today?
Investing.com -- Pics NV stock plunged 34.1% in pre-open trading to reach $9.10, extending a prolonged downtrend for the Brazilian digital payments and financial services company that has seen its shares slide well below their January 2026 IPO price of $19.00.
Raymond James reiterates Vera Therapeutics stock Strong Buy on kidney disease data
Investing.com - Raymond James reiterated a Strong Buy rating and $84.00 price target on Vera Therapeutics () stock. The target represents significant upside from the current price of $27.99, which sits 50% below its 52-week high of $56.05. The stock has faced headwinds with a 45% decline year-to-date, though analyst consensus remains bullish with a Strong Buy rating.
AST SpaceMobile secures spectrum authorization in Brazil
MIDLAND, Texas - AST SpaceMobile Inc. () announced today it has secured spectrum authorization from Brazil’s National Telecommunications Agency (Anatel) and signed agreements with four regional mobile network operators to support space-based cellular broadband services in the country. Anatel authorized 15+15 MHz of S-band spectrum, totaling 30 MHz, for AST SpaceMobile’s planned service in Brazil, according to a press release statement.
Soluna repays $28.7 million debt, cuts total principal by 76%
ALBANY, N.Y. - Soluna Holdings, Inc. () announced today it has fully repaid $28.7 million in principal outstanding under its credit facility with Generate Capital, PBC as of June 30, 2026, according to a press release statement. The company repaid $19.1 million of the Generate debt in August and paid the remainder in October, fully retiring the facility.
Medicus Pharma regains Nasdaq minimum bid price compliance
PHILADELPHIA - Medicus Pharma Ltd. () received written notice from Nasdaq on Friday confirming the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The notice followed Nasdaq’s determination that the closing bid price of the company’s common shares remained at or above $1.00 per share for ten consecutive business days, from October 12 through October 23, 2026, according to a press release statement.
Immuneering presents phase 3 pancreatic cancer trial design
NEW YORK - Immuneering Corporation () presented a poster Friday describing the design of its ongoing Phase 3 clinical trial evaluating atebimetinib in combination with modified chemotherapy for first-line metastatic pancreatic cancer at the European Society for Medical Oncology Congress in Madrid, according to a press release statement.
CAE to sell Flightscape unit to SITA for $500 million
MONTREAL - CAE Inc. (NASDAQ:CAE) () announced today it has entered into a definitive agreement to sell Flightscape, its airline operations software business, to SITA for an enterprise value of $500 million, subject to customary adjustments. The transaction is expected to close in the first half of 2027, pending regulatory approvals and satisfaction of remaining closing conditions, according to a press release statement.
Biohaven presents preclinical data on kidney disease drug candidate
NEW HAVEN, Conn. - Biohaven Ltd. () presented preclinical data for BHV-1420 on Saturday at the American Society of Nephrology Kidney Week 2026 in Denver, according to a press release statement. BHV-1420 is an investigational extracellular protein degrader designed to bind anti-PLA2R autoantibodies, which drive disease in most patients with membranous nephropathy. The molecule is designed to direct these autoantibodies to the liver for degradation.
Xilio doses first patient in lung cancer trial of XTX501
WALTHAM, Mass. - Xilio Therapeutics Inc. () announced today that it has dosed the first patient in a Phase 1/2 clinical trial of XTX501, a PD-1/masked IL-2 bispecific antibody, according to a press release statement. The trial is evaluating XTX501 in patients with metastatic non-small cell lung cancer who have previously received anti-PD(L)-1 therapy. The company said it anticipates reporting initial Phase 1 data in the fourth quarter of 2027.
Davion completes $25m acquisition of wound monitoring technology
DUBLIN - Davion Healthcare Plc () completed the acquisition of intellectual property for two medical technologies from Humaskan Ltd shareholders for $25 million, according to a press release statement issued today. The transaction includes WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform.
TuHURA reports tumor responses in 3-patient cancer trial
TAMPA, Fla. - TuHURA Biosciences Inc. () announced today preliminary results from the first three patients in an open-label study evaluating IFx-2.0 combined with Keytruda for metastatic Merkel Cell Carcinoma treatment, according to a press release statement. All three patients achieved partial responses under RECIST v.1.1 criteria at the six-month assessment. The responses remained ongoing at the protocol-specified evaluation point.
Why is StoneCo stock collapsing today?
Investing.com -- Shares of fell 34.7% in pre-open trading after Brazilian President Luiz Inácio Lula da Silva secured a surprise fourth term, defeating right-wing Senator Flávio Bolsonaro in Sunday’s presidential runoff with roughly 51.5% of the vote — a result that overturned market expectations and forced a rapid unwind of bets placed on a pro-market government.
FedEx appoints Jamere Jackson as chief financial officer
Published Oct 26, 2026, 07:22 AM Updated Oct 26, 2026, 07:48 AM FedEx appoints Jamere Jackson as chief financial officer FedEx appoints Jamere Jackson as chief financial officer In this article: Oct 26 (Reuters) - on Monday appointed Jamere Jackson as chief financial officer, effective November 30. Jackson will step down as CFO of on November 25.
Avio shares gain 4% as Berenberg sees sustained demand for rocket motors
Investing.com -- Shares of Italian rocket motor maker rose 4% after Berenberg upgraded the company to "buy" from "hold", saying the shortage of solid rocket motors for missiles is structural and U.S. missile makers want an independent supplier. Berenberg said the shortage has deepened because of ongoing conflicts. It said Avio has the experience to take market share.
Acumen Pharmaceuticals beats Q3 estimates, shares jump 6%
Investing.com -- On Monday, Acumen Pharmaceuticals Inc. () reported third quarter that exceeded analyst expectations. The clinical-stage biophharma company’s shares went up 5.56% in pre-market trading following the announcement. The company posted an adjusted loss per share of -$0.35 for the third quarter, beating the analyst consensus estimate of -$0.38 by $0.03.
Waraba Gold to acquire 80% stake in Côte d’Ivoire project
VANCOUVER - Waraba Gold Limited () (OTC Pink:WARAF) (FSE:ZE00) announced Sunday that it entered into an agreement to acquire an 80% interest in Leo Resources SARL from a subsidiary of Desert Metals Limited (), according to a press release statement. The transaction involves exploration licence PR-683, covering 212.66 square kilometers in northern Côte d’Ivoire.
Commercial Bank Q3 2026 slides: AI push supports strategy shift
Introduction & Market Context The (P.S.Q.C.) presented its financial results for the nine months ended September 30, 2026, on October 26, 2026, showcasing progress on its 2026-2030 strategic transformation while navigating a challenging operating environment. The Qatar-based lender reported net profit after tax of QAR 1.54 billion, down 13.8% year-over-year, as higher provisions and tax charges offset solid core banking performance.
Verizon beats profit estimates, raises guidance Original
Investing.com -- Verizon Communications Inc. () reported its third-quarter results before the open today, topping profit expectations. Adjusted earnings per share of $1.31 beat the analyst estimate of $1.28 by $0.03. Revenue came in at $34.31 billion, up 1.5% YoY, but fell short of the consensus estimate of $34.77 billion. The company raised its full-year 2026 adjusted EPS guidance to $5.04-$5.06, with a midpoint of $5.05 that exceeds the analyst consensus of $5.02.
BofA resumes AutoZone stock coverage with buy rating
Investing.com - BofA Securities resumed coverage on AutoZone Inc. () with a buy rating on Monday. The $51.8 billion auto parts retailer currently trades at a P/E ratio of 21.03 and has delivered 7.4% revenue growth over the last twelve months, with an impressive gross profit margin of 52%. The firm also resumed coverage on the auto parts sector with buy ratings on both AutoZone and .
Dot Ai appoints Avi Cohen to board following Envoy acquisition
WILMINGTON, Del. - CID HoldCo, Inc., doing business as Dot Ai (), announced today the appointment of Avi Cohen to its board of directors, according to a press release statement. Cohen previously served as CEO of RR Media, where he oversaw annual revenue of $140.3 million in 2015. RR Media was acquired by SES S.A. in 2016 for $242 million. He later became CEO of MX1, formed through the combination of RR Media and SES Platform Services.
Premarket movers: Moderna, Brazil ADRs drop; SpaceX rises
Here are some of the biggest premarket U.S. stock movers today: shares fell 9.3% in premarket trading as investors continued to react to Phase 3 results for intismeran autogene, the personalized mRNA cancer vaccine it is developing with Merck. Data from the INTerpath-001 trial, presented at the ESMO 2026 Congress in Madrid after leaking ahead of the official presentation on Oct. 22, showed that the vaccine combined with Keytruda reduced the risk of melanoma recurrence or death by 42%.
Earnings call transcript: Supreme Industries posts strong H1 FY2027 growth, shares fall
The Supreme Industries Limited reported strong first-half FY2027 growth in revenue, operating profit and profit after tax, but its shares fell 4.08% to $3,251.8 from the previous close of $3,390. The stock is now near the lower end of its 52-week range of $3,140 to $4,074.8. The company said revenue from operations rose 22% year over year in H1 to INR 6,079 crores, while operating profit climbed 34% and PAT increased 31%.
Baird raises Spotify stock price target on subscriber growth outlook
Investing.com - Baird raised its price target on Spotify Technology SA shares () to $675 from $570 while maintaining an Outperform rating. The stock currently trades at $584.22, near its 52-week high of $676.67, though InvestingPro data suggests the shares may be overvalued relative to its Fair Value estimate. The firm adjusted its estimates following the company’s third-quarter results.
Oppenheimer raises Microsoft stock price target on Azure demand
Investing.com - Oppenheimer raised its price target on Microsoft Corp. () to $625 from $570 while maintaining an Outperform rating. The stock currently trades at $524.51, which InvestingPro data suggests is undervalued based on its Fair Value analysis. The firm cited healthy enterprise demand supporting sustained momentum in Azure and Microsoft 365 ahead of the company’s first-quarter results.
Why is Alliance Resource Partners stock rallying today?
Investing.com -- Alliance Resource Partners stock surged 3.3% in pre-open trading after the Tulsa-based master limited partnership delivered a standout third-quarter 2026 earnings report before the market opened, with earnings per unit of $1.08 coming in well ahead of the consensus estimate of approximately $0.85 and even surpassing the more optimistic $0.98 forecast that Noble Financial had issued earlier this month.
BofA Securities resumes O’Reilly Automotive stock with buy rating
Investing.com - BofA Securities resumed coverage on O’Reilly Automotive Inc. () with a Buy rating, the firm said Sunday. The auto parts retailer, with a market cap of $72.74 billion, currently trades at a P/E ratio of 28.73 and has delivered 8.5% revenue growth over the last twelve months. Analyst Christopher Nardone reinstated coverage on the auto parts sector with Buy ratings on both O’Reilly Automotive and AutoZone Inc. (). The firm also resumed Advance Auto Parts Inc.
Earnings call transcript: Vodafone Qatar lifts 2026 outlook after Q3 growth
Vodafone Qatar reported revenue of QAR 896.96 million for the quarter, slightly below the QAR 905.91 million expected by analysts, while adjusted earnings came in at 0.049 per share. The company’s stock rose 3.2% to $2.42 from $2.345, suggesting investors focused more on the stronger full-year outlook, higher profitability and continued service-revenue growth than on the modest revenue miss.
Umios to acquire High Liner Foods for C$804 million
LUNENBURG, NS - High Liner Foods Incorporated () announced today it has entered into a definitive arrangement agreement with Umios Corporation () to be acquired for C$27.00 per share in cash, according to a press release statement. The transaction values High Liner Foods at approximately C$804 million on a fully diluted equity basis and C$1.25 billion on an enterprise value basis.
HEDGE FLOW-Trend hedge funds saw worst week since 2024 as AI stocks fell, Goldman says
LONDON, Oct 26 (Reuters) - Trend-following hedge funds witnessed their worst weekly performance in two years last week, as concern about the eventual pay-off from hefty AI spending ignited volatility across stocks and bonds, a Goldman Sachs note seen by Reuters on Monday showed. The , home to the world’s largest tech stocks, fell 5.5% last week, its biggest weekly fall since April 2025, when US President Donald Trump’s Liberation Day tariffs roiled world markets.
Rosenblatt lowers Galaxy Digital stock price target to $30 on market conditions
Investing.com - Rosenblatt lowered its price target on Galaxy Digital Holdings Ltd. () to $30 from $35 while maintaining a Buy rating on the stock. The shares currently trade at $15.06, sitting at their 52-week low and 62% below the 52-week high of $39.65, though InvestingPro analysis suggests the stock is undervalued at current levels. The firm issued the revised target Monday ahead of the company’s third-quarter 2026 results, which are scheduled for release Tuesday before market open.
Mizuho reiterates Oracle stock rating ahead of investor day
Investing.com - Mizuho reiterated an Outperform rating and $320.00 price target on Oracle Corporation () shares. The stock has faced headwinds recently, down 55% over the past year, though it currently trades at a P/E ratio of 19.98 with a PEG ratio of just 0.43, suggesting attractive valuation relative to growth prospects.
PostNL Q3 2026 slides: pricing gains offset volume pressure
Introduction & Market Context PostNL () presented its third-quarter 2026 trading update on October 26, reporting modest revenue growth and an improved free cash flow outlook despite significant headwinds from new European Union customs regulations. The Dutch postal and parcel delivery company’s shares rose 4.79% to $0.832 following the presentation, which showed disciplined execution of its volume-to-value strategy amid challenging market conditions.
Fragile Risk Appetite as Investors Prepare for a Crucial Week
Pivotal week as five central banks meet amidst weak risk appetite Equities face a crucial test from AI-related earnings this week Dollar seeks direction as oil prices remain elevated Gold slides to $4,000; will history repeat itself?
GXO expands humanoid robot deployment to two more sites
GREENWICH, Conn. and SALEM, Ore. - GXO Logistics Inc. () announced today an expansion of its partnership with Agility Robotics to deploy Digit humanoid robots at facilities in North Carolina and Tennessee, according to a press release statement. The expansion follows the companies’ initial agreement in 2024 to deploy Digit robots at a warehouse in Flowery Branch, Georgia.
MacroGenics reports interim results for lorigerlimab in cancer trial
ROCKVILLE, Md. - MacroGenics Inc. () announced interim results from its Phase 2 LINNET study evaluating lorigerlimab in patients with clear cell gynecologic cancer, according to a press release statement issued today. As of September 1, 2026, the study enrolled 41 patients with advanced gynecologic cancers, including 17 patients with clear cell gynecologic cancer.
Oruka reports positive phase 2b psoriasis trial results
MENLO PARK, Calif. - Oruka Therapeutics Inc. () announced today positive 16-week results from its EVERLAST-B Phase 2b trial evaluating ORKA-001, an IL-23p19 monoclonal antibody, for moderate-to-severe plaque psoriasis. The randomized, double-blind, placebo-controlled trial enrolled 187 patients across 36 sites in the United States, Canada, and Europe. Patients were randomized to receive either 37.5 mg ORKA-001 at Week 0, 300 mg at Weeks 0 and 4, 600 mg at Weeks 0 and 4, or placebo.
Regeneron extends Ebola treatment supply deal with US government
TARRYTOWN, N.Y. - Regeneron Pharmaceuticals Inc. () has extended its agreement with the Biomedical Advanced Research and Development Authority to supply additional doses of Inmazeb, an Ebola treatment, according to a press release statement issued today. The agreement adds approximately $270 million in value to a procurement arrangement that began in 2020. Regeneron expects to deliver additional treatment doses to the U.S. government through 2031.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with James
Contact James, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack